208 related articles for article (PubMed ID: 16801644)
1. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.
Pierantozzi M; Pietroiusti A; Brusa L; Galati S; Stefani A; Lunardi G; Fedele E; Sancesario G; Bernardi G; Bergamaschi A; Magrini A; Stanzione P; Galante A
Neurology; 2006 Jun; 66(12):1824-9. PubMed ID: 16801644
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
Lee WY; Yoon WT; Shin HY; Jeon SH; Rhee PL
Mov Disord; 2008 Sep; 23(12):1696-700. PubMed ID: 18649391
[TBL] [Abstract][Full Text] [Related]
3. Eradication of Helicobacter pylori in follicular and nonfollicular gastritis.
Mehmet S; Ozdal E; Kamil O; Beşir K; Huseyin D; Nihat A; Cigdem EY; Nusret E
Hepatogastroenterology; 2009; 56(91-92):930-4. PubMed ID: 19621732
[TBL] [Abstract][Full Text] [Related]
4. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial.
Rostami N; Keshtkar-Jahromi M; Rahnavardi M; Keshtkar-Jahromi M; Esfahani FS
Am J Hematol; 2008 May; 83(5):376-81. PubMed ID: 18183613
[TBL] [Abstract][Full Text] [Related]
5. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Bergemann N; Baas H; Fischer PA
Nervenarzt; 1994 Apr; 65(4):250-7. PubMed ID: 8015632
[TBL] [Abstract][Full Text] [Related]
6. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson's disease patients: A prospective cohort study (HP-PD trial).
Lolekha P; Sriphanom T; Vilaichone RK
PLoS One; 2021; 16(5):e0251042. PubMed ID: 33945559
[TBL] [Abstract][Full Text] [Related]
7. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial.
de Leest HT; Steen KS; Lems WF; Bijlsma JW; van de Laar MA; Huisman AM; Vonkeman HE; Houben HH; Kadir SW; Kostense PJ; van Tulder MW; Kuipers EJ; Boers M; Dijkmans BA
Helicobacter; 2007 Oct; 12(5):477-85. PubMed ID: 17760715
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection.
Narożańska E; Białecka M; Adamiak-Giera U; Gawrońska-Szklarz B; Sołtan W; Schinwelski M; Robowski P; Madaliński MH; Sławek J
Clin Neuropharmacol; 2014; 37(4):96-9. PubMed ID: 24992088
[TBL] [Abstract][Full Text] [Related]
9. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori.
Lyte M
Med Hypotheses; 2010 May; 74(5):895-7. PubMed ID: 19962247
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial.
De Leest HT; Steen KS; Bloemena E; Lems WF; Kuipers EJ; Van de Laar MA; Bijlsma JW; Janssen M; Houben HH; Kostense PJ; Boers M; Dijkmans BA
J Clin Gastroenterol; 2009 Feb; 43(2):140-6. PubMed ID: 18797408
[TBL] [Abstract][Full Text] [Related]
11. Effect of cranberry juice on eradication of Helicobacter pylori in patients treated with antibiotics and a proton pump inhibitor.
Shmuely H; Yahav J; Samra Z; Chodick G; Koren R; Niv Y; Ofek I
Mol Nutr Food Res; 2007 Jun; 51(6):746-51. PubMed ID: 17487928
[TBL] [Abstract][Full Text] [Related]
12. Eradication of Helicobacter pylori infection might improve clinical status of patients with Parkinson's disease, especially on bradykinesia.
Liu H; Su W; Li S; Du W; Ma X; Jin Y; Li K; Chen H
Clin Neurol Neurosurg; 2017 Sep; 160():101-104. PubMed ID: 28704778
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
Blindauer K; Shoulson I; Oakes D; Kieburtz K; Schwid S; Fahn S; Stern M; Goetz C; Nutt J; Goren S; Sayag N; Scolnik M; Levy R; Eyal E; Salzman P; Pagano M;
Arch Neurol; 2006 Feb; 63(2):210-6. PubMed ID: 16476809
[TBL] [Abstract][Full Text] [Related]
14. Azithromycin effect on helicobacter pylori eradication: double blind randomized clinical trial.
Rogha M; Pourmoghaddas Z; Rezaee M; Shirneshan K; Shahi Z
Hepatogastroenterology; 2009; 56(91-92):722-4. PubMed ID: 19621690
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
Cindoruk M; Erkan G; Karakan T; Dursun A; Unal S
Helicobacter; 2007 Aug; 12(4):309-16. PubMed ID: 17669103
[TBL] [Abstract][Full Text] [Related]
16. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia.
Vakil N; Talley NJ; Stolte M; Sundin M; Junghard O; Bolling-Sternevald E
Aliment Pharmacol Ther; 2006 Jul; 24(1):55-63. PubMed ID: 16803603
[TBL] [Abstract][Full Text] [Related]
17. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
18. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
Pierantozzi M; Pietroiusti A; Sancesario G; Lunardi G; Fedele E; Giacomini P; Frasca S; Galante A; Marciani MG; Stanzione P
Neurol Sci; 2001 Feb; 22(1):89-91. PubMed ID: 11487216
[TBL] [Abstract][Full Text] [Related]
19. Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study.
Cheon JH; Kim JH; Lee SK; Kim TI; Kim WH; Lee YC
Helicobacter; 2008 Dec; 13(6):564-71. PubMed ID: 19166423
[TBL] [Abstract][Full Text] [Related]
20. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
